Technology Portfolio / Spin-Offs

Technology-based Spin-Off companies:

Seqplexing was founded in 2013 with the aim of developing solutions for research and clinical applications based on advanced genetic techniques and platforms, particularly next-generation sequencing (NGS). The company addresses the need for reliable protocols for amplicon and gene sequencing by developing ready-to-use solutions that can be easily implemented in laboratories.

Seqplexing’s mission is to support laboratories that, due to the demands of their day-to-day activities, lack the time or resources to develop optimised protocols for sequencing genes or regions of interest. The company transforms the components required for these techniques into commercial kits, providing a comprehensive service covering the entire workflow, from sample preparation to the final analysis of results.

Epidisease was founded in 2014 as a result of a project led by researchers from INCLIVA and the Biomedical Research Networking Centre (CIBER) in the field of Rare Diseases, with the aim of translating expertise in epigenetics and biomedical sciences into solutions that benefit society.

Epigenetics studies the factors and mechanisms involved in regulating gene expression. The importance of this field continues to grow, as findings arising from initiatives such as the Human Genome Project have shown that the molecular basis of cellular function, development, ageing and many diseases extends far beyond the DNA sequence itself. More recent findings from the Roadmap Epigenomics Project have further advanced our understanding of these mechanisms.

Epidisease’s mission is to leverage its extensive expertise in epigenetics to provide its clients with biomedical solutions, diagnostic tools and new therapies, while promoting translational research aimed at improving human health and well-being.

Nela BioDynamics is a biomedical technology development company that emerged from collaboration within the Valencian university ecosystem. Its multidisciplinary team brings together researchers with expertise in biomedicine and engineering.

The company originated from the results of a Master’s Thesis in Biomedical Engineering, which led to two patents covering a novel intramedullary fixation system for joint endoprostheses, fracture nails and exoprostheses, as well as a percutaneous collar for ostomies.

NELA’s intramedullary implant technology enables a personalised fit for each patient and avoids conventional fixation techniques based on impact press-fitting or the use of bone cement. This can result in shorter surgical procedures, reduced pain, improved success rates and a better quality of life for patients.

NELA’s mission is to address unmet medical needs while generating a positive socioeconomic impact.

ARTHEx BIOTECH is a spin-off company from the Universitat de València developing advanced RNA-based therapies for genetic diseases. Its team has extensive expertise in drug discovery and in the role of microRNAs in neuromuscular diseases. The company is also supported by internationally renowned scientific and clinical advisors who contribute their expertise to the successful development of its therapeutic programmes.

ARTHEx Biotech’s mission is to develop effective treatments for unmet medical needs. Its initial focus is on investigating anti-microRNA therapies for the treatment of myotonic dystrophy type 1 (DM1), a rare disease affecting more than 900,000 people worldwide, with an estimated prevalence of 1 in 8,000.